Doctors and the pharmaceutical industry: time for a national policy?

Jennifer H Martin, Christopher Beer, Raymond G Morris and Matthew P Doogue
Med J Aust 2009; 191 (3): . || doi: 10.5694/j.1326-5377.2009.tb02741.x
Published online: 3 August 2009

To the Editor: We share Millar’s concerns about the conflicts of interest that influence the genesis and adoption of clinical guidelines1 specifically, and the lack of independent assessment regarding information provided by the pharmaceutical industry generally. Iain Chalmers puts it succinctly:

  • 1 Royal Brisbane and Women’s Hospital, Brisbane, QLD.
  • 2 Western Australian Centre for Health and Ageing, Perth, WA.
  • 3 Queen Elizabeth Hospital, Adelaide, SA.
  • 4 Flinders Medical Centre, Adelaide, SA.

  • 1. Millar JA. Genesis of medical thromboprophylaxis guidelines in Australia: a need for transparency and standardisation in guideline development. Med J Aust 2009; 190: 446-450. <MJA full text>
  • 2. Royal College of Physicians. Innovating for health. Patients, physicians, the pharmaceutical industry and the NHS. Report of a Working Party. London: RCP, 2009: 4.
  • 3. Olver IN, Haines IE. What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century? Med J Aust 2009; 190: 74-77. <MJA full text>
  • 4. Van Der Weyden MB. Doctors and the pharmaceutical industry: time for a national policy [editorial]? Med J Aust 2009; 190: 407-408. <MJA full text>


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.